Lataa...
Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib
Icotinib hydrochloride is an orally administered small-molecule reversible tyrosine kinase inhibitor that has been independently researched and developed and has independent intellectual property rights in the People’s Republic of China. Clinical trials have demonstrated that the response to icotini...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2014
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4037325/ https://ncbi.nlm.nih.gov/pubmed/24876785 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S49233 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|